Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Ulrich Mrowietz, MD
University Medical Center Schleswig-Holstein
Kiel, Germany

Ulrich Mrowietz is a Professor of Dermatology and the founder of the Psoriasis Center in the Department of Dermatology at the University Medical Center Schleswig-Holstein, Campus Kiel, Germany. His main research areas in psoriasis include management strategies, drug development, and basic research. The Psoriasis Center provides a large clinical trial unit and is part of the Comprehensive Center for Inflammation Medicine at the Kiel Campus.

Professor Mrowietz is the author or co-author of more than 375 peer-reviewed publications listed in the Medline database and numerous other publications in the field. His h-Index is 65. In addition, he is the author of chapters in multiple psoriasis textbooks, including Braun-Falco’s Dermatology and Venerology.

From 2004 to 2019, Professor Mrowietz was Editor-in-Chief of Archives of Dermatological Research. He is a former member of the Executive Board of the German Dermatological Society, a councilor of the International Psoriasis Council, a member of the scientific advisory board of the German Psoriasis Association, a member of the Clusters of Excellence “Inflammation at Interfaces” and “Precision Medicine in Chronic Inflammation,” and of numerous dermatological societies. Professor Mrowietz was President of the 6th World Psoriasis and Psoriatic Arthritis Conference in June/July 2021 in Stockholm, Sweden.

Last Updated: Mar 08, 2022


PUBLICATION

Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 Pandemic: Findings from a Global Patient-Reported Cross-Sectional Survey. Cook E, Dand N, Yiu Zenas Zee N, et al. Br J Dermatol. 2022 Feb 1. doi: 10.1111/bjd.21042. Epub ahead of print. PMID: 35104366.

Why this article was chosen

The COVID-19 pandemic has been a significant concern, and vaccination has been crucial worldwide in its combat. The IPC has followed the developments around COVID-19, issued several statements, and provided information through expert videos and commentaries. The IPC has supported collecting real-world data on COVID-19 and psoriasis (PsoProtect and PsoProtectMe registries). Recently Cook et al (Br J Dermatol 2022 (online first)) reported on the interruption of psoriasis care during the COVID-19 pandemic and vaccine hesitancy in patients with psoriasis.

Commentary

Sudden pandemic situations are a significant threat to people with known chronic illnesses representing an additional unexpected burden. Those with limited psycho-social resources and lower resilience are more likely to withdraw from regular care and seek help or information. However, the high proportion of people with psoriasis having interrupted access to care (40.1%), as described in the report by Cook et al, is unexpected. Still, in this report, the data were collected from a multi-national survey (PsoProtectMe) in 89 countries worldwide on 802 patients with psoriasis. In addition, psoriasis patients having interrupted access to care had increased vaccine hesitancy, were more prevalent in non-white ethnic groups, had shorter disease duration, and were less likely to take systemic immunosuppressants.

It is important to note that the disruption of care can be bi-directional. The affected people stopped seeing their treating physicians, but physicians also canceled patients’ appointments. It is worth noting that younger people with psoriasis and more severe disease were more likely to discontinue care, and the rate of vaccine hesitancy was higher in this group. The authors did not speculate about factors driving this coincident finding. This may be due to greater engagement of younger people through social media, in which worries and concerns (e.g., a new type of vaccine, fear of adverse events, etc) are intensively discussed and amplified without direct physician’s input. However, and encouragingly, the rate of vaccine hesitancy, which was 8.3% in the entire patient population, seems low and provides evidence that stakeholders providing care in the different healthcare systems can get through to people with psoriasis.

As reported by Cook et al, these data help identify groups that need correct and unbiased information based on solid and accurate evidence-based medicine.

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

  


IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis
 

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK